DSpace Repository

Effects of Chemically-Modified-Curcumin (CMC2.24) on Rat Experimental Periodontitis

Show simple item record

dc.contributor.advisor Gu, Ying en_US
dc.contributor.advisor Golub, Lorne M en_US
dc.contributor.author Wang, Howard Hao en_US
dc.contributor.other Department of Oral Biology and Pathology en_US
dc.date.accessioned 2017-09-20T16:50:43Z
dc.date.available 2017-09-20T16:50:43Z
dc.date.issued 2016-12-01 en_US
dc.identifier.uri http://hdl.handle.net/11401/76590 en_US
dc.description 63 pgs en_US
dc.description.abstract Periodontal disease is one of the most common chronic inflammatory diseases, and causes severe debilitation due to the loss of teeth. There are two main strategies utilized in the treatment of periodontal disease: (1) local mechanical therapy, such as scaling and root planing and/or periodontal surgery, as well as local adjunctive antimicrobial (Atridox, Arestin, and Periochip) therapy, and (2) addition of an adjunctive therapy such as host-modulation therapy (HMT). Regarding the latter, there is currently only one systemically administered FDA-approved medication for the treatment of chronic periodontitis, Periostat®, a non-antimicrobial doxycycline-based MMP-inhibitor, which was developed decades ago. The current study assessed a novel NON-tetracycline or NON-doxycycline-based host-modulation medication, which is a triketonic (rather than diketonic like doxycycline), chemically-modified curcumin 2.24 (CMC2.24), and was tested for efficacy in reducing periodontal bone loss in a rat model of experimental periodontitis. Periodontitis was induced in 50 adult male rats by repeated local injection of phosphate buffered saline (PBS; control) or lipopolysaccharide/endotoxin (LPS; experimental) into the gingiva. Experimental groups were orally administered either curcumin or CMC2.24 (30mg/kg), whereas the untreated LPS rats and PBS rats received vehicle alone. Both the prophylactic and therapeutic models were employed. The 20 rats in Experiment 1 (the prophylactic protocol) were injected with either PBS or LPS, and at the same time, systemically administered daily with the vehicle, or curcumin or CMC2.24 for 2-weeks via oral gavage. The 30 rats in Experiment 2 (the therapeutic protocol) were sub-divided into Experiment 2A (1-week duration of CMC2.24) or 2B (2-weeks duration of CMC2.24) to assess the therapeutic effects of different durations of treatment AFTER periodontal disease had already been established. After sacrifice, gingival tissue, blood, and alveolar bone were collected and analyzed. The jaws were dissected, defleshed, photographed, and bone loss was measured morphometrically and radiographically. The gingival extracts and blood samples were analyzed for matrix metalloproteinases (MMP-2 and MMP-9) by gelatin zymography, and cytokines by ELISA. In general, the LPS group with no treatment exhibited increased MMP-2 and MMP-9, cytokines (IL-1β, TNF-α) and alveolar bone loss. CMC2.24 was found to be more effective than curcumin in reducing MMPs, cytokines and alveolar bone loss. CMC2.24 treatment significantly reduced the periodontal bone loss in the rats in both the prophylactic and therapeutic models of drug administration; regarding the latter model, 2-weeks of treatment was required since the shorter duration (1-week) did not show significant effects except for a reduction in MMP-9. This study found that systemic administration of CMC2.24, a novel triketonic zinc-binding chemically-modified curcumin, reduced both local and systemic inflammation by modulating the production of cytokines and MMPs and attenuated periodontal bone loss in experimental periodontitis in both the prophylactic and therapeutic models. en_US
dc.description.sponsorship This work is sponsored by the Stony Brook University Graduate School in compliance with the requirements for completion of degree. en_US
dc.format Monograph en_US
dc.format.medium Electronic Resource en_US
dc.language.iso en_US en_US
dc.publisher The Graduate School, Stony Brook University: Stony Brook, NY. en_US
dc.subject.lcsh Dentistry -- Medicine -- Pharmaceutical sciences en_US
dc.subject.other Anti-inflammatory, Chemically Modified Curcumin (CMC2.24), Host modulation, Matrix metalloproteinase, Periodontal Disease, Rat Periodontitis Model en_US
dc.title Effects of Chemically-Modified-Curcumin (CMC2.24) on Rat Experimental Periodontitis en_US
dc.type Thesis en_US
dc.mimetype Application/PDF en_US
dc.contributor.committeemember Carrion, Julio A en_US
dc.contributor.committeemember Simon, Sanford R en_US
dc.contributor.committeemember Johnson, Francis en_US

Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace

Advanced Search


My Account